CHGA

Across TCGA pan-cancer cohorts, CHGA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHGA data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHGA mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CHGA expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where CHGA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	1.000	0.485	<.001	99	view →
LUAD	DFS	Quartile	II,III,IV	0.214	0.808	.006	46	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	28	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	26	view →
GBM	OS	Quartile	All	0.344	0.701	.033	5	view →
LSCC	DFS	Median	All	0.433	1.000	.013	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHGA–PDAC (OS)

Open the PDAC breakdown →